H1N1型流感病毒血凝素抑制肽的筛选研究  

Selection and identification of H1N1 influenza virus hemagglutinin inhibitory peptides

作　　者：汪崇文[1] 丁晓然[2] 杨静[2] 邓新秀 高婵 冯指泉[2] 鲁丹丹[2] 王升启[2] 

机构地区：[1]安徽医科大学,合肥230032 [2]军事医学科学院放射与辐射医学研究所,北京100850 [3]杭州天龙药业有限公司,杭州310021

出　　处：《国际药学研究杂志》2013年第1期48-52,共5页Journal of International Pharmaceutical Research

基　　金：十二五国家科技重大专项"活性产物合成及分离制备平台"(2012ZX09301003-001-004);国家自然科学基金项目(30901825)

摘　　要：目的以流感病毒血凝素(HA)为作用靶点,筛选新型抗流感多肽药物。方法通过噬菌体展示技术,从随机十二肽库中筛选HA结合肽,并对筛选获得的多肽进行细胞及鸡胚水平的抗H1N1活性验证。结果筛选获得了9条HA结合肽,其中H6具有显著的抗病毒活性,其抑制A/FM1/1/47(H1N1)、A/PR/8/34(H1N1)两株流感病毒致细胞病变的IC50值分别为37.3和48.5μmol/L,抑制两株病毒在鸡胚内复制的IC50值分别为26.7和33.4μmol/L。结论 H6有显著的抗H1N1活性,具有开发成新型抗流感病毒药物的潜力。Objective Using the influenza virus hemagglutinin（HA） as the target to screen for novel anti-influenza polypeptide drugs.Methods The HA binding peptides were screened out through affinity selection from a 12-peptide phage library,and the anti-H1N1 activity was evaluated at MDCK cell and chicken embryo（ovo）.Results Nine HA binding peptides were finally obtained,and the H6 peptide was found having significant antiviral activity against H1N1.Its IC50 against two strains of H1N1,A/FM1/1/47（H1N1） and A/PR/8/34（H1N1）,were 37.3 and 48.5 μmol/L respectively determined by cytopathic effect（CPE）test,and 26.7 and 33.4 μmol/L respectively measured by ovo antiviral experiment.Conclusion These results showed that H6 might be a potential therapeutic drug for H1N1 infection.

关 键 词：流感病毒 血凝素结合肽 抑制肽 噬菌体展示 

分 类 号：R392[医药卫生—免疫学]